 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic...

Prime Medicine to Present at Upcoming Investor Conferences

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Prime Medicine price target lowered to $18 from $19 at Morgan Stanley

-- Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems...

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

In trading on Friday, the ARK Genomic Revolution ETF is outperforming other ETFs, up about 7.9% on the day. Components of that ETF showing particular strength include shares of Nurix Therapeutics...

Video: Friday's ETF Movers: ARKG, URA

Up to 83% of Hepatocytes (up to 50% whole liver) Precisely Edited for p.L358fs Mutation Following IV Infusion of Prime Editor in NHPs with No Safety Concerns Observed; Editing Well Above Anticipated...

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

New In Vivo Data in Humanized Mouse Model Demonstrate that Prime Editing Can Correct Predominant Mutations Accounting for Approximately 60% of Patients with RHO adRP Up to 70% Precise Correction at...

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

Prime Medicine initiated with an Outperform at BMO Capital

Investors considering a purchase of Prime Medicine Inc (PRME) stock, but cautious about paying the going market price of 8.50/share, might benefit from considering selling puts among the...

Commit To Purchase Prime Medicine At $5, Earn 7.4% Annualized Using Options

CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime ...

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Watchers	406
52-Wk Low	$5.54
52-Wk High	$21.48

Market Cap	$784.43M
Volume (M)	444,175.00
52-Wk High	$21.48
52-Wk Low	$5.54

PRME Prime Medicine Inc

About

Feed

News

Sentiment

Earnings

Fundamentals